Form 4: Amgen EVP, Operations, Esteban Santos, Reports Stock Transactions

Esteban Santos, EVP of Operations at Amgen, reports the disposition of 606 shares of common stock to cover tax obligations related to vested Restricted Stock Units (RSUs) and the acquisition of shares through the company's 401(k) plan.

Summary

• On May 2, 2024, Esteban Santos, EVP of Operations at Amgen, filed a Form 4 indicating changes in beneficial ownership of Amgen stock.
• Santos disposed of 606 shares of common stock at a price of $277.37 per share to satisfy tax obligations related to vested Restricted Stock Units (RSUs).
• Following the transaction, Santos directly owns 68,924 shares of Amgen common stock, which includes various RSUs vesting at different dates in the future.
• Santos also indirectly owns 856.6105 shares through the company's 401(k) plan.
• The reported holdings include Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. The sale of shares is likely for tax purposes, and the executive still holds a significant amount of stock.

Positives

• The reporting person continues to hold a significant number of shares in the company, indicating confidence in Amgen's future.

Future Outlook

The document does not contain explicit forward-looking statements, but it details the vesting schedule of RSUs through 2027.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry commonly include stock options and restricted stock units (RSUs) to align management's interests with those of shareholders.
• The vesting schedules of Amgen's RSUs are typical for the industry, with vesting occurring over several years to incentivize long-term performance.
• Companies like Gilead Sciences, Biogen, and Regeneron also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transaction itself is unlikely to have a significant impact on stakeholders, as it is a routine disclosure.
• However, transparency in insider transactions is important for maintaining investor confidence.

Key Dates